Tonia A. Douglas
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Tonia A. Douglas has a total of 54 co-authors. Here are the top co-authors by number of shared publications:
- Claire Elizabeth Wainwright
Department of Respiratory and Sleep Medicine, Queensland Children’s Hospital, South Brisbane, Queensland, Australia
4 shared publications - Vanessa Elise Cobham
School of Psychology, The University of Queensland, Brisbane, Australia
2 shared publications Adeline Y. L. Lim
Department of Respiratory and Sleep Medicine Queensland Children's Hospital South Brisbane Australia
1 shared publication- Ahmad Reza Pourghaderi
School of Public Health and Preventive Medicine, Monash University, Victoria, Australia
1 shared publication Alexandra L Quittner
Joe DiMaggio Cystic Fibrosis, Pulmonary and Sleep Center, Hollywood, Florida, USA
1 shared publicationAnna M Georgiopoulos
Division of Child and Adolescent Psychiatry, Massachusetts General Hospital, Boston, Massachusetts, USA
1 shared publication
Latest Publications
- 30 December 2025
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 25 (2) , 369-374
The impact of telehealth on clinical outcomes in adults and children with cystic fibrosis in Australia
- 30 December 2025
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 25 (2) , 369-374
The impact of telehealth on clinical outcomes in adults and children with cystic fibrosis in Australia
- Open Access
- 1 October 2025
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 211 (10) , 1896-1897
Hitting the Sweet Spot: The Impact of Elexacaftor/Tezacaftor/Ivacaftor on Glucose Tolerance in Cystic Fibrosis
- 1 October 2025
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 211 (10) , 1896-1897
Open AccessHitting the Sweet Spot: The Impact of Elexacaftor/Tezacaftor/Ivacaftor on Glucose Tolerance in Cystic Fibrosis
- Open Access
- 10 February 2025
- Published by BMJ in BMJ Open Respiratory Research
- Vol. 12 (1) , e002606
Psychosocial and mental health in cystic fibrosis in the modern era of care: time to evolve
Cystic fibrosis (CF) treatment has revolutionised care over the past three decades with major advances in survival. Despite these advances, CF continues to create psychological and social challenges for people with CF (PWCF) throughout their life and is associated with worse health outcomes and higher healthcare costs. Anxiety and depression screening and management protocols are widely implemented within CF care; however, a much broader scope of psychosocial challenges exist which lack a standardised screening and management approach. The advent of CF transmembrane conductance regulator modulator therapies is transforming the psychosocial landscape for PWCF with new challenges and evolving psychosocial needs. What it means to have CF, the expectations, hopes and stressors are rapidly changing, and psychosocial care must keep pace if health outcomes are to be fully optimised. A symposium of international CF and psychosocial experts was convened in November 2022 to explore current and emerging issues in psychosocial health and identify opportunities and approaches to optimise psychosocial care. This state-of-the-art review summarises key symposium proceedings and highlights priorities for clinical practice and research in psychosocial health across the lifespan among PWCF. It also summarises state-of-the-art initiatives for screening and intervention to optimise CF psychosocial healthcare and patient outcomes.
- 10 February 2025
- Published by BMJ in BMJ Open Respiratory Research
- Vol. 12 (1) , e002606
Open AccessPsychosocial and mental health in cystic fibrosis in the modern era of care: time to evolve
Cystic fibrosis (CF) treatment has revolutionised care over the past three decades with major advances in survival. Despite these advances, CF continues to create psychological and social challenges for people with CF (PWCF) throughout their life and is associated with worse health outcomes and higher healthcare costs. Anxiety and depression screening and management protocols are widely implemented within CF care; however, a much broader scope of psychosocial challenges exist which lack a standardised screening and management approach. The advent of CF transmembrane conductance regulator modulator therapies is transforming the psychosocial landscape for PWCF with new challenges and evolving psychosocial needs. What it means to have CF, the expectations, hopes and stressors are rapidly changing, and psychosocial care must keep pace if health outcomes are to be fully optimised. A symposium of international CF and psychosocial experts was convened in November 2022 to explore current and emerging issues in psychosocial health and identify opportunities and approaches to optimise psychosocial care. This state-of-the-art review summarises key symposium proceedings and highlights priorities for clinical practice and research in psychosocial health across the lifespan among PWCF. It also summarises state-of-the-art initiatives for screening and intervention to optimise CF psychosocial healthcare and patient outcomes.
- 28 October 2024
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 24 (3) , 571-573
Mental health, behaviour and sleep quality in children 6–11 years before and after elexacaftor/tezacaftor/ivacaftor initiation
- 28 October 2024
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 24 (3) , 571-573
Mental health, behaviour and sleep quality in children 6–11 years before and after elexacaftor/tezacaftor/ivacaftor initiation
- Open Access
- 12 April 2024
- Published by Wiley in Pediatric Pulmonology
- Vol. 59 (6) , 1661-1676
SHIFTing goals in cystic fibrosis—managing extrapulmonary disease in the era of CFTR modulator therapy; Proceedings of the International Shaping Initiatives and Future Trends (SHIFT) Symposium
Background: Cystic fibrosis (CF) is a life‐shortening multisystem genetic disease. Although progressive pulmonary disease is the predominant cause of morbidity and mortality, improvements in treatment for CF‐related lung disease, with associated increase in longevity, have increased the prevalence of extrapulmonary manifestations1.Methods: To discuss these issues, a multidisciplinary meeting of international leaders and experts in the field was convened in November 2021 at the Shaping Initiatives and Future Trends Symposium with the goal of highlighting shifting management paradigms in CF. The main topics covered were: (1) nutrition and obesity, (2) exocrine pancreas, (3) CF‐related diabetes, (4) CF liver disease, (5) CF‐related bone disease, and (6) post‐lung transplant care. This document summarizes the proceedings, highlighting the key priorities and important research questions that were discussed.Results: Improved life expectancy, the advent of cystic fibrosis transmembrane conductance regulator modulators, and the increasing appreciation of the heterogeneity or spectrum of disease are leading to a shift in management for patients with cystic fibrosis. Care should be individualized to ensure that increased longevity is accompanied by improved extra‐pulmonary care and reduced morbidity.
- 12 April 2024
- Published by Wiley in Pediatric Pulmonology
- Vol. 59 (6) , 1661-1676
Open AccessSHIFTing goals in cystic fibrosis—managing extrapulmonary disease in the era of CFTR modulator therapy; Proceedings of the International Shaping Initiatives and Future Trends (SHIFT) Symposium
Background: Cystic fibrosis (CF) is a life‐shortening multisystem genetic disease. Although progressive pulmonary disease is the predominant cause of morbidity and mortality, improvements in treatment for CF‐related lung disease, with associated increase in longevity, have increased the prevalence of extrapulmonary manifestations1.Methods: To discuss these issues, a multidisciplinary meeting of international leaders and experts in the field was convened in November 2021 at the Shaping Initiatives and Future Trends Symposium with the goal of highlighting shifting management paradigms in CF. The main topics covered were: (1) nutrition and obesity, (2) exocrine pancreas, (3) CF‐related diabetes, (4) CF liver disease, (5) CF‐related bone disease, and (6) post‐lung transplant care. This document summarizes the proceedings, highlighting the key priorities and important research questions that were discussed.Results: Improved life expectancy, the advent of cystic fibrosis transmembrane conductance regulator modulators, and the increasing appreciation of the heterogeneity or spectrum of disease are leading to a shift in management for patients with cystic fibrosis. Care should be individualized to ensure that increased longevity is accompanied by improved extra‐pulmonary care and reduced morbidity.
- 1 May 2021
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 20 (3) , 511-515
Early disease surveillance in young children with cystic fibrosis: A qualitative analysis of parent experiences
- 1 May 2021
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 20 (3) , 511-515
Early disease surveillance in young children with cystic fibrosis: A qualitative analysis of parent experiences
- 4 March 2021
- Published by Springer Nature in Clinical Child and Family Psychology Review
- Vol. 24 (2) , 370-390
Anxiety in Children with Cystic Fibrosis and Their Parents: A Systematic Review
Individuals with cystic fibrosis (CF) are at high risk of clinically significant anxiety, which can be related to lower treatment adherence and poorer health outcomes. Additionally, up to half of the parents/caregivers of children with CF experience clinically significant anxiety. Research has focussed on CF youth aged 13 years and older, leaving anxiety among school-aged children (aged 6–12 years) largely unstudied. This review aimed to synthesize research on anxiety among children with CF and their parents, examining prevalence, risk factors, and relationships between parent and child factors. Four electronic databases were searched, and publications were included if participants were children (or parents of children) with CF with a mean age between 6 and 12 years, and a standardized anxiety measure was used. Data from fourteen studies were extracted for descriptive synthesis; however, no studies focussed exclusively on the age range of 6–12 years. Results generally indicated that anxiety is highly prevalent in both child and parent populations; anxiety was the most prevalent mental health condition among children with CF, and anxiety was higher among CF populations than control populations among both children and parents. However, there were disparities, with some papers finding low rates of anxiety, and results on the relationship between anxiety and health outcomes varying greatly. Several risk factors were identified, but few were corroborated. There is an overall deficiency of research in this area, particularly examining the relationships between parent and child anxiety, and anxiety and health outcomes. Further research on suitable screening and intervention practices is also required.
- 4 March 2021
- Published by Springer Nature in Clinical Child and Family Psychology Review
- Vol. 24 (2) , 370-390
Anxiety in Children with Cystic Fibrosis and Their Parents: A Systematic Review
Individuals with cystic fibrosis (CF) are at high risk of clinically significant anxiety, which can be related to lower treatment adherence and poorer health outcomes. Additionally, up to half of the parents/caregivers of children with CF experience clinically significant anxiety. Research has focussed on CF youth aged 13 years and older, leaving anxiety among school-aged children (aged 6–12 years) largely unstudied. This review aimed to synthesize research on anxiety among children with CF and their parents, examining prevalence, risk factors, and relationships between parent and child factors. Four electronic databases were searched, and publications were included if participants were children (or parents of children) with CF with a mean age between 6 and 12 years, and a standardized anxiety measure was used. Data from fourteen studies were extracted for descriptive synthesis; however, no studies focussed exclusively on the age range of 6–12 years. Results generally indicated that anxiety is highly prevalent in both child and parent populations; anxiety was the most prevalent mental health condition among children with CF, and anxiety was higher among CF populations than control populations among both children and parents. However, there were disparities, with some papers finding low rates of anxiety, and results on the relationship between anxiety and health outcomes varying greatly. Several risk factors were identified, but few were corroborated. There is an overall deficiency of research in this area, particularly examining the relationships between parent and child anxiety, and anxiety and health outcomes. Further research on suitable screening and intervention practices is also required.
- 1 May 2020
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 19 (3) , 483-491
Health-related quality-of-life in children with cystic fibrosis aged 5-years and associations with health outcomes
- 1 May 2020
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 19 (3) , 483-491
Health-related quality-of-life in children with cystic fibrosis aged 5-years and associations with health outcomes
- 13 December 2017
- Published by Wiley in Journal of Clinical Nursing
- Vol. 27 (3-4) , e590-e599
Family‐centred care for families living with cystic fibrosis in a rural setting: A qualitative study
Aims and objectives: To explore experiences of family‐centred care among parents of children with cystic fibrosis living far from tertiary treatment centres and to understand what such distances mean to their care.Background: Australia is a large continent. However, many families with a child with cystic fibrosis live in regional areas, often thousands of kilometres away from the primary treatment centres located in Australia's coastal capital cities.Design: A qualitative, phenomenological design using a Van Manen () approach.Methods: Individual, semi‐structured interviews were conducted with parents (n = 7) of a child with cystic fibrosis who lived in regional Australia. Thematic content data analysis was used.Results: The essence of the participants’ experience was their seeking certainty and continuity in the changeable realm of cystic fibrosis while negotiating a collaborative approach to their child's care. Five core themes and two subthemes were identified: “Daily care: a family affair,” including the subtheme “Accessing expert care”; “Family‐centred care: seeking inclusion”; “Control versus collaboration: seeking mutual trust,” with the subtheme “The team who grows with you”; “Future projections”; and “The CF circle.”Conclusion: Some concerns are not unlike those of their city counterparts, but can be intensified by their sense of distance and isolation.Relevance to clinical practice: Insight into this unique milieu from the parents’ perspective is requisite so that care is appropriate to such a challenging environment and incorporates the whole family.
- 13 December 2017
- Published by Wiley in Journal of Clinical Nursing
- Vol. 27 (3-4) , e590-e599
Family‐centred care for families living with cystic fibrosis in a rural setting: A qualitative study
Aims and objectives: To explore experiences of family‐centred care among parents of children with cystic fibrosis living far from tertiary treatment centres and to understand what such distances mean to their care.Background: Australia is a large continent. However, many families with a child with cystic fibrosis live in regional areas, often thousands of kilometres away from the primary treatment centres located in Australia's coastal capital cities.Design: A qualitative, phenomenological design using a Van Manen () approach.Methods: Individual, semi‐structured interviews were conducted with parents (n = 7) of a child with cystic fibrosis who lived in regional Australia. Thematic content data analysis was used.Results: The essence of the participants’ experience was their seeking certainty and continuity in the changeable realm of cystic fibrosis while negotiating a collaborative approach to their child's care. Five core themes and two subthemes were identified: “Daily care: a family affair,” including the subtheme “Accessing expert care”; “Family‐centred care: seeking inclusion”; “Control versus collaboration: seeking mutual trust,” with the subtheme “The team who grows with you”; “Future projections”; and “The CF circle.”Conclusion: Some concerns are not unlike those of their city counterparts, but can be intensified by their sense of distance and isolation.Relevance to clinical practice: Insight into this unique milieu from the parents’ perspective is requisite so that care is appropriate to such a challenging environment and incorporates the whole family.